-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Solid Tumor Drug Details: NKTR-255 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Non-Hodgkin Lymphoma Drug Details: NKTR-255 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Metastatic Colorectal Cancer Drug Details: NKTR-255 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Cervical Cancer Drug Details: NKTR-255 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Anal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Anal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Anal Cancer Drug Details: NKTR-255 is under development for...
-
Product Insights
NewDry Powder Inhaler Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. GlobalData's Medical Devices sector report, “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Dry Powder Inhaler Devices report...
-
Product Insights
NewNet Present Value Model: GSK plc’s Depemokimab
Empower your strategies with our Net Present Value Model: GSK plc's Depemokimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Nektar Therapeutics Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Nektar Therapeutics Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Relapsed Multiple Myeloma Drug Details: NKTR-255 is under...